Durvalumab相关论文
1 文献来源rnPaz ? Ares L, Dvorkin M, Chen Y, et al.Durvalumab plus platinum?etoposide versus platinum?etoposide in first......
durvalumab是由阿斯利康公司研发的完全人源化的抑制程序性死亡配体1(PD-L1)的Ig G1单克隆抗体。2017年5月1日,美国食品和药物管理......
1 文献来源rnAntonia SJ,Villegas A,Daniel D,et al. Overall survival with Durvalumab after chemoradiotherapy in stageⅢNSC......
期刊
Deep diving in the PACIFIC:Practical issues in stage III non-small cell lung cancer to avoid shipwre
After publication of the PACIFIC trial results,immune checkpoint inhibitor-based immunotherapy was included in the treat......
美国FDA于2017年5月1日批准阿斯利康(Astrazeneca)公司的Durvalumab(商品名:Imfinzi)注射液上市,用于局部晚期或转移性尿路上皮癌......
期刊
目的该研究的目的主要是估算durvalumab在Ⅲ期非小细胞肺癌(NSCLC)同步放化疗以后巩固治疗中中国地区的成本效果性。方法基于大型......
1文献来源Paz-Ares L,Dvorkin M,Chen Y,et al.Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line tr......
1文献来源Antonia SJ,Villegas A,Daniel D,et al.Overall survival with Durvalumab after chemoradiotherapy in stageⅢNSCLC[J......
<b>Background: </b>Immune checkpoint inhibitors have made a great novelty in the treatment of various cancer types, show......
BACKGROUND Programmed cell death-1(PD-1)inhibitor has been indicated for many types of malignancies.However,these inhibi......
<正>美国FDA于2018年2月16日批准阿斯利康公司(Astra Zeneca)的Imfinzi(durvalumab,度伐鲁单抗)增加新的适用症,即用于治疗3期非小......
<正>【简评】Ⅲ期非小细胞肺癌(non-small cell lung cancer,NSCLC)约占初诊肺癌的30%,基于淋巴结受累情况可切除性存在很大差异。......
